According to appleinsider news, the British start-up company Rockley Photonics is going to be listed on the New York Stock Exchange in the near future. Judging from the documents submitted by the company to the US Securities and Exchange Commission SEC, this company has an important connection with Apple, and the company’s blood glucose measurement technology is expected to be introduced in Apple Watch Series 7 in 2022. It could be Apple Watch Series 7 rumors.
Rockley Photonics, headquartered in the UK, designs and develops technology that uses infrared to monitor human blood. The sensor can not only measure heart rate, blood oxygen but also monitor blood sugar and even alcohol levels. According to the SEC documents, Rockley disclosed financial information, stating that Apple is one of the company’s few large customers. The top two customers accounted for 99.6% of the company’s revenue in 2019 and 100% in 2020. It is not yet clear how much Apple accounts for in its sales, and the name of another major customer is also unknown. Foreign media said that this start-up company is signing a supply and development agreement with Apple. In the future, the company’s main income will continue to rely on Apple and another major customer.
IT Home learned that foreign media learned that Rockley Photonics CEO Andrew Rickman said that the technology developed by the company will be applied to consumer products in 2022, but declined to disclose whether it is related to Apple.
There have been rumors that Apple is studying a method for measuring blood sugar using Apple Watch, and Apple has also announced a patent for measuring blood sugar without drawing blood. If Rockley Photonics’ technology development is successful, it will greatly improve the convenience of blood glucose monitoring for people with diabetes in the future, and avoid the pain of blood sampling and measurement.
